We believe there is an unmet need for chronic pain worldwide that provides an opportunity for plant medicine as a 2nd line therapy after NSAIDs.
The TGA has recommended to physicians that opiates are now not to be a recommended prescription medicine for pain patients.
We believe that plant medicines may be a good 2nd line therapy for pain patients worldwide.
We also believe that there are further exciting developments to be made around the various chemicals within plants. Cymra Life Sciences is researching all compounds of plant medicines and testing them in formulations to understand how they may work in synergy to treat inflammation and pain.
Thorough clinical research and product development we are aiming to establish a registered plant medicine with the TGA, FDA and EMA.
Cymra has now completed a Phase II dose escalation and efficacy study in 28 patients where they have not responded or tried opiate medications.
Phase III is planned for 2024.
Cymra has launched as Superbly Green and Rainbow Cannabis into the Australian flower market with its organic living soil grown flower.
There is a strong demand worldwide for organic plant medicines worldwide.
We breed our own strains on the Northern Rivers and use tissue culture propagation methods to create unique high health cultivars.
Our organically grown products and clinical development plan are based on extracts which preserve the balance of the whole plant and terpenes.
We are a science backed company developing clinical and agricultural data to make the ideal products for our patients.